NR and NMN Both Double Circulating NAD+ Levels in Clinical Trial
NAD+, or nicotinamide adenine dinucleotide, is a coenzyme essential for cellular energy production and DNA repair. Its levels decline steadily with age, dropping to roughly half of youthful concentrations by the time we reach our 60s. For researchers and consumers focused on longevity, that decline has made NAD+ restoration one of the most scrutinized targets in the supplement space. Two 2026 clinical trials now add meaningful data to a question that’s been hard to answer cleanly: which NAD+ precursor actually works?
Head-to-Head: NR vs. NMN vs. Regular Nicotinamide
A January 2026 randomized, placebo-controlled trial enrolled 65 healthy adults and split them into three groups, each receiving either NR (nicotinamide riboside), NMN (nicotinamide mononucleotide), or NAM (nicotinamide, the form of vitamin B3 found in most multivitamins). The primary measure was circulating NAD+ concentration in blood.
Both NR and NMN doubled circulating NAD+ levels. NAM did not produce a statistically significant change.
What makes this trial particularly valuable is its direct comparison design. Prior research showed each precursor could raise NAD+ in isolation, but head-to-head data under identical conditions was scarce. The study found no significant difference between the NR and NMN groups, suggesting the two are functionally equivalent for NAD+ elevation based on current evidence.
The NAM finding is worth underscoring. Many consumers assume that vitamin B3 in any form will elevate NAD+, but the biosynthesis routes are distinct. NR and NMN enter more direct pathways to NAD+ production, whereas NAM is processed through a different enzymatic route that appears rate-limited, at least at the doses tested.
Niagen NR in Long COVID: Promising Within-Group Results
A separate 24-week, randomized, double-blind, placebo-controlled study focused on a different population: 58 non-hospitalized adults experiencing Long COVID, with a mean age of 45.1. Participants received 2,000mg per day of Niagen NR (ChromaDex’s proprietary NR ingredient) for 20 weeks.
NAD+ levels peaked at 3.1-fold above baseline at 5~10 weeks into supplementation. Within the treatment group, researchers observed improvements in fatigue, sleep quality, depressive symptoms, and executive functioning (the cluster of cognitive skills involved in planning, focus, and decision-making).
However, statistically significant differences between the treatment group and placebo group were not observed. The researchers themselves point to the small sample size and high dropout rate as key limitations that constrain interpretation. Lead researcher Dr. Edmarie Guzmán-Vélez of Rutgers University led the study. Co-author Dr. Charles Brenner, Chief Scientific Advisor to Niagen Bioscience, has a declared interest in the outcome, which is standard to note when evaluating commercially funded research.
The study does not establish that NR is an effective treatment for Long COVID. What it does is justify a larger, adequately powered trial to test whether the within-group signals observed here hold up under more rigorous conditions.
What This Means for Supplement Decisions
The two trials together sharpen a few practical questions for anyone already thinking about NAD+ supplementation.
NR and NMN appear equivalent. The 2026 head-to-head data gives no reason to prefer one over the other on efficacy grounds. Price becomes a more relevant differentiator. NMN generally costs more per dose than NR, while NR products at 300~1,000mg per dose run roughly $25~60 per month depending on brand and dose.
Regular vitamin B3 does not substitute. If you’re already taking a multivitamin or B-complex, check whether the B3 included is niacin (nicotinic acid), niacinamide, or nicotinamide. Based on this trial, none of these are expected to significantly raise circulating NAD+. NR and NMN are structurally distinct precursors with different metabolic routes.
The 2,000mg dose in the Long COVID study is high. Standard commercial NR products typically recommend 300~500mg daily, occasionally up to 1,000mg. The research-grade dose of 2,000mg has limited precedent in commercial use, and whether that dose level is necessary for general longevity purposes, versus acute post-viral recovery, remains an open question.
Caution for those on medications. NAD+ metabolism intersects with pathways relevant to certain medications, including those that affect sirtuins or PARP enzymes. Anyone managing a chronic condition or taking prescription drugs should consult a healthcare provider before introducing high-dose NAD+ precursors.
The science on NR and NMN continues to advance. These two trials add confidence that raising NAD+ is achievable through supplementation, that NR and NMN are the more effective routes compared to regular vitamin B3, and that the effects extend to a population managing Long COVID symptoms, though the clinical significance there still needs larger study.
Is NR better than NMN?
In this trial, both NR and NMN roughly doubled circulating NAD+ with no significant difference between them. Choose based on personal response, price, and formulation preference.
Why doesn’t regular vitamin B3 (nicotinamide) work?
The study found that NAM did not raise circulating NAD+ levels. NR and NMN feed into more direct NAD+ biosynthesis pathways, bypassing the rate-limiting steps that NAM encounters.
What dosage should I take?
The Long COVID study used 2,000mg/day NR. Most commercial NR supplements range from 300~1,000mg per dose, costing roughly $25~60 per month. The NAD+ doubling study’s exact dose was not publicly detailed.